Patent intelligence · US
US 11939368
QTY Fc fusion receptor proteins
QTY Fc fusion receptor proteins
Patent details — US 11939368
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 26, 2024
- Expiration
- Mar 21, 2044
- Applicant
- Avalon GloboCare Corp.
- Claims
- 4
- CPC classes
- A61K, A61K38/00, A61K38/177, A61K45/06
Quick answer
US 11939368 (QTY Fc fusion receptor proteins) is held by Avalon GloboCare Corp.. Status: granted. Granted Mar 26, 2024. Expires Mar 21, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Avalon GloboCare Corp.
- Grant date
- Expiration
- Claims
- 4
- CPC classes
- A61K, A61K38/00, A61K38/177, A61K45/06, A61K47/68
More from Avalon GloboCare Corp.
Related pharmaceutical patents in our USPTO index.
-
US 12410153
Compounds, compositions and methods
granted -
US 12331107
Methods of treating pneumonia or respiratory failure associated with COVID-19 by administering an anti-LIGHT antibody
granted -
US 11898180
Compositions and methods for amino acid depletion therapy
granted -
US 11850243
Dihydropyridine compositions and methods for treating neurological disorders
granted -
US 11708406
Method of treating acute respiratory distress syndrome (ARDS) or acute lung injury (ALI) associate with COVID-19 by administering an anti-LIGHT antibody
granted -
US 11555060
QTY FC fusion water soluble receptor proteins
granted -
US 11479576
Nucleic acid prodrugs
granted
Frequently asked questions
What is US patent 11939368?
US 11939368 (QTY Fc fusion receptor proteins) is held by Avalon GloboCare Corp.. Status: granted. Granted Mar 26, 2024. Expires Mar 21, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11939368?
Avalon GloboCare Corp. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 10 pharmaceutical patents for this assignee.
When does US 11939368 expire?
Our index shows an expiration date of Mar 21, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.